The object of this study was to further localize autoantigenic structures on Ilb-Ila and, if possible, to precisely identify the epitopes recognized by human autoantibodies. In this paper, we identify a 50-kD chymotryptic fragment of i11a that is recognized by a high percentage of human autoantibodies, typified by the prototype IgG autoantibody RA, which binds to I11a on intact platelets as well as in an immunoblot assay under nonreduced conditions. Using an immunoblot assay, a carboxy-terminal region of this fragment (33 kD) that contains the cysteine-rich domains of i11a was found to carry the epitope(s) recognized by the prototype autoantibody RA. The amino-terminal amino acid sequence of the reduced 33-kD fragment, the smallest fragment that retains the RA epitope, is XPSQQDEXSP, and that of the reduced 50-kD fiagment is IVQVTFD. This indicates that the 33-kD fragment consists of -175 amino acids beginning at residue 479 and extending at least through residues 636-654, while the 50-kD fragment spans the same region but begins at residue 427. It is apparent that the 33-kD fragment is generated from the 50-kD fragment by additional chymotryptic hydrolysis but remains associated because of the multiple disulfide bonds that are characteristic of this cysteine-rich domain. Sera from 48% of patients with chronic ITP and 2 of8 patients with acute ITP contain antibodies that bind to the 50-kD fragment in an ELISA. Antibodies of the same specificity are also found in one-third of patients with either secondary immune thrombocytopenia or apparent nonimmune thrombocytopenia. We conclude that the 50-kD cysteine-rich region of lIla is a frequent target of autoantibodies in ITP, but that such antibodies may also be present in cases of thrombocytopenia that cannot be linked to an apparent autoimmune process. (J. Clin. Invest. 1991. 88:847-854.)
Introduction
The glycoprotein Ilb-IIIa complex ofhuman platelets is known to carry a number of clinically important alloantigens and autoantigens. This conclusion was initially based upon comparisons ofplatelets from normal subjects and patients with GlanzDr. Thomas J. Kunicki mann's thrombasthenia, which are deficient in this glycoprotein complex (1, 2) . The first indication that the pIA alloantigen system is located on this glycoprotein complex was derived in studies ofplatelets from Glanzmann's thrombasthenia patients (3) . Subsequent studies have confirmed this finding and have localized two other alloantigen systems, Bak and Pen, to IIb and IIIa, respectively (4) (5) (6) (7) (8) (9) .
The first report suggesting a preponderance ofautoantibodies against Ilb-Illa showed that thrombasthenic platelets fail to react with autoantibodies from a subgroup of patients with autoimmune thrombocytopenia (10). In an immunoblot assay, Beardsley et al. were able to specifically identify IIIa as a target antigen in a majority of patients with chronic autoimmune thrombocytopenia (1 1). Autoantibodies specific for Ilb have also been identified in at least two patients (12) .
The importance of IIb-IIIa as a carrier of autoantigens in both chronic and acute ITP has been firmly established using novel MAb-based ELISA and RIAs (13) (14) (15) (16) . Based on these reports, as many as one-halfofpatients with chronic idiopathic (autoimmune) thrombocytopenic purpura (ITP)' have circulating autoantibodies specific for the IlIb-IIIa complex.
In this study, we further localize a region of IIIa that contains antigens recognized by a high percentage of autoantibodies from patients with ITP.
Methods
Blood samples. Blood samples from 131 patients with suspected idiopathic (autoimmune) thrombocytopenia, as determined by the referring physicians, were included in this study. All patients also had laboratory findings of elevated direct platelet-associated IgG and/or IgM, by nephelometry (17) , as well as serum antibodies reactive with intact platelets, by ELISA (9) . All patients were suspected of having autoimmune thrombocytopenia alone or in combination with other causes of thrombocytopenia. In 70 of these 131 patients, clinical histories were available (see Table I ) and revealed that in 39 patients (54%) ITP (either acute or chronic) was felt to be the primary cause of the thrombocytopenia. In 31 patients (46%) other causes of thrombocytopenia were apparent, including secondary ITP (6 patients), drug-dependent immune thrombocytopenia (7 patients), and nonimmune thrombocytopenia (18 patients).
Antibodies. To identify antibodies that also react with denatured platelet antigens, plasma samples were analyzed in an immunoblot assay using total platelet protein as the target. Several antisera reactive with Illa were identified in this manner, including RA and SD. Each of these antisera react only with nonreduced Illa, a finding consistent with the original observation of Beardsley et al. (1 1) . Since RA antiserum contains exceptionally high levels ofantibody, it was used as the prototype for further studies of the epitopes recognized by this subset of autoantibodies. Anti-PI"A antisera were used as a positive control for the binding ofhuman antibodies. The murine MAbs AP2 (anti-Ilb-Illa 1. Abbreviations used in thispaper: ACE, antigen-capture ELISA; ITP, idiopathic thrombocytopenic purpura; MACE, modified ACE; PRP, complex) (18), AP4 (anti-Ilb heavy chain) and AP5 (anti-IIIa) were used as specific markers of the respective glycoproteins. AP4 and AP5 bind specifically to Ilb and Ilia, respectively, in an immunoblot assay of nonreduced and denatured platelet proteins (see Fig. 1 ). Murine IgG antibodies were purified from ascites fluid by HPLC using ABX columns (Whatman, Inc., Hillsboro, OR). Rabbit polyclonal antisera specific for glycoproteins Ilb and IIIa were a gift from Dr. D. Pidard (U. 150 INSERM, Paris, France). The sequence ofglycoprotein i11a has been determined (19) , and antibodies specific for individual peptide sequences of lIla have been developed. Rabbit polyclonal antibody specific for the i11a amino-terminal sequence I -13 (ab 1) was a gift from Drs. J. Beer and B. Coller (Stony Brook, NY). Rabbit polyclonal antibody against another peptide derived from the sequence ofIlla (amino acids 636-654) was generously supplied by Drs. S. D'Souza and E. Plow (Scripps Research Foundation, La Jolla, CA).
Biotinylation ofantibodies. 1 ml of purified murine IgG (0.5 mg/ ml) in 0.1 M NaHCO3, pH 7.4, was mixed with 0.06 ml of biotin (1 mg/ml; NHS-LC Biotin; Pierce Chemical Co., Rockford, IL) and incubated for 4 h at ambient temperature. The reaction was stopped by dialyzing the mixture against PBS, pH 7.4, containing 0.1% NaN3 at 4°C overnight.
Isolation ofplatelets. 6 vol of blood were mixed with 1 vol acid-citrate-dextrose solution (ACD; NIH formula A) and centrifuged at 250 g for 10 min at ambient temperature to obtain platelet-rich plasma (PRP). Prostaglandin El (PGE,; Sigma Chemical Co., St. Louis, MO) was added to the PRP to a final concentration of 20 ng/ml. After a 15-min incubation, the PRP was centrifuged at 750 g for 10 min to sediment platelets. After three washes with Ringer's citrate-dextrose (RCD), pH 6.5 (20) , the platelet pellet was resuspended in an appropriate buffer, and the platelet concentration determined using a Coulter Counter (Coulter Electronics, Hialeah, FL).
Antigen-capture ELISA (ACE). The ACE was performed as described by Furihata et al. (9) using solid-phase AP2 to capture IIb-IIIa or solid phase AP5 to capture the 50-kD chymotryptic fragment of IIIa (see below).
Modified antigen-capture ELISA (MACE). 50 Ml ofpurified murine monoclonal AP5 IgG (10 jig/ml) in 0.05 M sodium carbonate buffer, pH 9.6, were added to each well of a flat-bottomed 96-well microtiter plate (Immunolon II; Dynatech Laboratories, Inc., Alexandria, VA) and incubated at 4°C overnight. The wells were then blotted dry and incubated with 67 mM Na2PO4, 67 mM NaHPO4, 150 mM NaCl, pH 7.4, containing 0.05% (vol/vol) Tween 20 (PBS-Tween) and 1% (wt/ vol) gelatin at ambient temperature for 30 min to block the remaining binding sites. Washed platelets were sensitized by incubating 4 x 107 platelets in 0.1 ml of RCD-PGE1 with an aliquot of the primary antibody (100-400 Ml ofantisera or [1] [2] [3] [4] [5] [6] 7.4, plus 50 ng/ml PGE, with 0.1 U/ml ofthrombin at 37°C for 5 min. The reaction was stopped by adding hirudin (Sigma Chemical Co.) at a final concentration of 1 U/ml. The platelets were washed twice with RCD-PGE1 and either fixed with paraformaldehyde for flow cytometry (as described above) or suspended in Tris-glycine buffer for detergent lysis (as described below).
Solubilization ofplatelets in Triton X-100. Platelet lysates were prepared as described previously by Furihata et al. (21) . In brief, platelets were suspended in 9 vol of 33 mM Tris, 100 mM glycine, pH 8.7, at a concentration of 5,000 x 109/liter and mixed with 1 vol of 10% (vol/ vol) Triton X-100 in the same buffer. Lysates were centrifuged at 80,000 g for 30 min at 4°C. The protein concentration ofthe supernatant was determined using the method of Markwell et al. (22) .
Purification ofplatelet IIb-IIIa. The Ilb-II1a complex was isolated as described by Fitzgerald et al. (23) . Platelets from 50 U of outdated platelet concentrates served as the source of IlbIlIla and were lysed in Triton X-100 as described above. Con A-Sepharose was used to adsorb a lIb-IlIa-enriched fraction that was eluted from the column with amethyl-D-mannose. The major contaminants, thrombospondin and fibrinogen, were then removed by passing the material over a heparinSepharose column and subsequent gel filtration with Sephacryl S-300. Trace amounts of fibrinogen still contaminating the preparation were removed by wheat germ agglutinin affinity chromatography. The purity of the final preparation was evaluated by SDS-PAGE and ELISA using murine MAbs specific for platelet glycoproteins.
Proteolysis ofpurified IIb-IIa. The protein concentration of purified IlIb-IlIa was adjusted to 0.64 mg/ml. The amount of the different proteases used is expressed as the ratio of the weight of the protease to the weight of Ilb-Illa. Chymotrypsin digestion was performed at 37°C for 16-20 h with an enzyme to protein ratio of 1:7 in 20 mM Tris, 100 mM NaCl, 3 mM CaCl2, pH 7.8. To terminate digestion, PMSF was added to a final concentration of 1 mM.
Immunoblot assay. Detection of immunoreactive proteolytic fragments of IIb-IlIa was performed by an immunoblot assay. SDS-PAGE was performed as described (24) using a Laemmli buffer system and 7, 10, 12.5, or 15% polyacrylamide resolving slab gels. Proteins were then transferred electrophoretically to 0.2 Mm pore-size nitrocellulose (BioRad Laboratories) or to polyvinylidine difluoride (PVDF, Immobilon P; Millipore, Bedford, MA) membranes. In general, the nitrocellulose or PVDF membrane and the gel were first equilibrated in transfer buffer (192 mM glycine, 25 mM M Tris, 20% methanol, pH 8.3). However, in selected experiments, proteins were first reduced in the polyacrylamide gel by equilibrating the entire slab gel in transfer buffer containing 5% 2-mercaptoethanol for 45 min at ambient temperature. Blotting was carried out at 30 V for 30 min and then at 60 V for 3 h (4°C). After blotting, the remaining reactive sites of the nitrocellulose or PVDF membrane were blocked by incubating the sheets in PBS-Tween containing 0.05% NaN3. If the membranes were not to be stained immediately, they were allowed to air-dry and stored in airtight plastic bags between two filter papers (No. 1; Whatman, Inc.) at -20'C. The membrane was then washed three times for 10 min in PBS-Tween. The same buffer containing 0.5% FCS was used to dilute either the antisera or purified antibodies. The membrane strips were incubated with the primary antibody overnight (16-20 h) at ambient temperature on a shaker, washed three times for 10 min and incubated with a 1:1,000 dilution of alkaline phosphatase-conjugated goat antibodies against human, rabbit, or mouse IgG (Zymed Laboratories, Inc.) or with a 1:1,500 dilution of alkaline phosphatase-conjugated streptavidin (when biotinylated primary antibodies were used). After 3 h, the strips were washed an additional three times and then incubated with a freshly prepared substrate solution. The substrate solution consisted of 66 Ml of a stock solution of nitroblue tetrazolium (NBT; 50 mg/ml in 70% dimethylformamide) and 33 Ml of a stock solution bromo-4-chloro-3-indolylphosphate (BCIP; 50 mg/ml in 100% dimethylformamide) in 10 ml of 100 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 9.5. To stop color development, the membranes were rinsed in distilled water for 10 min and allowed to dry.
Immunoaffinity purification of the core chymotryptic fragment of IIIa. Immobilized streptavidin (Pierce Chemical Co.) was used to capture biotinylated murine MAb AP5. Biotinylated AP5 was mixed with streptavidin-agarose (1 Mg AP5 plus 5Mg ofstreptavidin) and incubated at ambient temperature for 4 h. The beads were washed three times in 25 mM Tris, 150 mM NaCl, pH 7.4, containing 0.05% Tween to remove unbound AP5. The chymotryptic digest of Ib-IlIa, to which was added 1 mM PMSF, 2 mM EDTA and 3 mM EGTA, was mixed with the AP5-streptavidin such that the molar ratio between AP5 and the major chymotryptic fragment of II1a was estimated to be 1:1. The mixture was incubated at 4°C overnight with agitation and then transferred to a disposable polypropylene column (Econo-column; Bio-Rad Laboratories). Unbound material was collected, and the column was washed with three column volumes of Tris-saline buffer, and one column volume of distilled water. Finally, bound proteins were eluted using three column volumes of 100 mM glycine, pH 2.2. The eluate was immediately neutralized by collecting it into a pretitrated volume of 1 N NaOH, dialyzed against 5 mM Tris, pH 6.8, containing 0.1 mM PMSF, and evaporated to dryness (Speed-Vac; Savant Instruments, Hicksville, NY) or concentrated using a Micro-Pro-Dicon unit (10,000 mol wt cutoff; Bio-Molecular Dynamics, Beaverton, OR). Microsequencing of protein fragments was performed for a fee by the Protein Sequencing Facility of the Medical College of Wisconsin, Milwaukee, WI, using a protein sequencer (No. 477A; Applied Biosystems, Inc., Foster City, CA).
Results
Initial characterization of the human autoantibody RA. The specificity of RA for IIb-IIIa was first established by modified antigen capture ELISA (MACE) using murine MAb, AP2, to capture JIb-IlIa from platelet lysates presensitized with autoantibodies. RA also reacted with Ilb-IIIa in the ACE (9), wherein solid-phase AP2 was used to capture Ilb-IIIa from platelet lysates before reaction with primary antibody. Immunoblotting ofplatelet lysates prepared from the patient's platelets as well as platelets ofPAl or PI'2 homozygous donors confirmed that RA antibody binds to a protein migrating as IIa. The binding of RA antibody is independent of pIA or Pen polymorphisms which are both expressed on IIIa (9, 25) .
Autoreactive epitopes were further characterized using purified Ilb-IlIa in an immunoblot assay (Fig. 1) . In addition to a prominent Ila band with an apparent molecular mass of 93 kD, high molecular mass bands at -210 and 165 kD that likely represent dimers and multimers of lIla (26) Autoreactive epitopes on proteolytic fragments ofpurified JIb-lIla. The conditions for extensive digestion ofJIb-I1a with chymotrypsin were established in order to obtain the smallest fragment of i11a still reactive with RA. The results of digestion with chymotrypsin for 16-20 h at 370C, using a protease to substrate ratio of 1:7, are depicted in Fig. 2 . By immunoblot assay, under nonreduced conditions, the ability of chymotryptic fragments to be bound by polyclonal rabbit anti-I1b and anti-lila, as well as autoantibody RA and MAb AP5 was tested. The starting material contained intact Ilb but also Ilb fragments with apparent molecular masses of 66, 41, and 35 kD (lane A). However, the majority of i11a was intact, only a small amount of a 65-kD fragment detectable (lane C). After digestion, the only remnant of Ilb detectable was a trace fragment at 27 kD (lane B). Thus glycoprotein Ilb had been completely digested by this procedure. On the other hand, fragments of Ila corresponding to 65, 50, 38, and 33 kD were detected (lane D), the predominant fragment being that at 50 kD. Autoantibody RA binds to intact lIIa (lane E) and the three II1a fragments with apparent molecular masses under nonreduced conditions of 50, 38, and 33 kD (lane F). AP5 reacts with intact II1a (lane G) and the predominant 50-kD lIIa fragment (lane H). Upon reduction of disulfide bonds, the reactivity of the 50-kD fragment with both RA and AP5 was lost (data not shown). To further characterize the chymotryptic fragments, they were separated under nonreduced conditions and subsequently reduced within the same polyacrylamide gel before transfer to nitrocellulose membrane (Fig. 3) . Rabbit anti- epitopes as determined by an immunoblot assay.
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II and I11a fiagments were separated by SDS-PAGE using a 12.5% polyacrylamide resolving gel under nonreduced conditions. Intact I1b- IIIa  (lanes A, C, E, G) (Fig. 4) . kDa -100 2) -50 or anti-IIla,13 (lanes 3 and 4) to chymotryptic fragments of IIIa. The proteolytic fragments were separated by SDS-PAGE -33 using a 12.5% polyacrylamide resolving gel. After electrophoresis but before electrotransfer for the immunoblot assay, the proteins were reduced in situ by incubating the gel in 5% 2-mercaptoethanol. Lanes I and 3 contain intact I1b-11-a; lanes 2 and 4, the chymotryptic digest. Molecular masses (kD) are depicted to the right of the gel. These data suggest that the "50" kD fragment seen on nonreduced gels actually represents a composite of disulfide-bonded fragments. In conclusion, RA reacts only with nonreduced chymotryptic fragments of II1a that bind anti-IIIa63",U. We find no evidence that the amino-terminus ofIIIa is required for autoantibody reactivity. In fact, the smallest fragment reacting with autoantibody, the 33-kD fragment, does not carry the amino-terminal epitope recognized by anti-I1Ia1,13.
Additional results. In ACE using AP5, the nonreduced 50-kD fragment was bound by both RA and anti-PlAl antibodies. Thus, the AP5 epitope is distinct from sites recognized by antiPIAl or RA antiserum because the binding of AP5 did not inhibit the binding of the latter antibodies.
By direct antigen ELISA, purified Ib1IlIla or the AP5-affinity purified 50-kD fragment were used to screen for additional autoantibodies against IIb-IIIa that were not detectable by the immunoblot assay. Sera from 131 patients with suspected autoimmune thrombocytopenia were assayed. Clinical follow-up was obtained on 70 patients such that they could be categorized as having: primary ITP (39 patients), secondary ITP (6 patients), drug-induced immune thrombocytopenia (7 patients), or nonimmune thrombocytopenia (18 patients) (see Table I ). Although the binding of human autoantibodies is normally weaker than the binding ofanti-PlAl orAP5, we detected significantly positive reactions with sera from 33 patients (Tables I  and II) . These Table II , the two patients whose sera gave the strongest positive reactions in the ELISA did not have ITP; the former presented with chronic liver disease and alcoholism; the latter appears to have a mild form ofthe Bernard-Soulier syndrome. 20 sera reacted with the 50-kD fragment but bound marginally, if at all, to intact IIb-IIIa. Of 13 sera (including RA) that were positive for IIb-IIIa, 12 also bound to the 50-kD fragment.
These data confirm that the 50-kD fragment contains autoantigens frequently encountered in autoimmune thrombocytopenia but also indicate that such antibodies are not restricted to ITP. The data also demonstrate that two classes of antigens exist: those like RA that are expressed on intact IIIa as well as the fragment; and a second group that may represent neoantigens that are cryptic on the intact IIIa molecule.
Discussion
There is increasing evidence of the importance of IIb-IIla as a carrier of autoantigens in chronic ITP. As many as one-half of patients with chronic ITP may have circulating autoantibodies specific for platelet membrane glycoprotein lIb-fIla (14, 16) . A study of the binding characteristics of certain autoantibodies against 1Ib-IIla, based upon their ability to compete with the binding of four murine monoclonal antibodies, argues that the number of autoantigenic epitopes is not small (27) . However, competitive binding between human autoantisera and murine MAbs can only give a general impression ofthe number ofand relationship between autoepitopes. But, heterogeneity of autoantigens on Ilb-Illa is also reflected in the finding that certain, albeit a minority of autoantibodies induce platelet dysfunction without causing destruction (28, 29) , while the majority are associated with significant thrombocytopenia. None of the epitopes recognized by human autoantisera reactive with lIb-Illa have been precisely identified. One human monoclonal autoantibody against lila, 5E5 (30) binds predominantly to activated or altered platelets suggesting that the epitope is cryptic. Tomiyama et al. (12) have characterized two autoantisera against the 1Ib heavy chain that react with a chymotryptic 65 kD fragment (reduced molecular mass) retained by platelets after proteolysis. The only autoantigenic epitope that has been precisely identified is that recognized by another human monoclonal autoantibody, 2E7 (31) . 2E7 binds to an epitope defined by the sequence 231-238 of lIb that is destroyed by proteolysis with chymotrypsin (31) .
In this study, we present a more systematic approach to the characterization ofprototypical autoantigenic epitopes on IIIa.
We selected the immunoblot assay, which had been successfully applied to this problem earlier by Beardsley et al. (1 1), as one of the initial screening procedures. This approach defined an epitope(s) that is recognized by a particularly strong autoantiserum, the RA prototype, which is only expressed by nonreduced IIIa. Although RA antiserum was initially detected by its strong reactivity with denatured II1a, it has consistently reacted with intact platelets, platelet membranes or purified IIb-IIIa in all of the assays used in this study.
To further localize the RA epitope(s) on IIIa, we used the immunoblot assay to assess the binding of RA autoantibodies to electrophoretically separated chymotryptic fragments of IIIa. Our aim was to define the smallest fragment retaining the RA epitope(s). Results obtained with RA were compared with those obtained with the murine MAb AP5 and human anti-P1AI. Earlier, this approach led to the localization of the PIAl epitope to a 66-kD chymotryptic fragment of II1a (32) and the Baka epitope to the carboxy-terminal portion of the IIb heavy chain (6) . The RA epitope is expressed by a number ofchymotryptic fragments, ranging from 33 to 50 kDa, whereas AP5 and anti-PlAl only react with the 50-kD species. Polyclonal rabbit antibodies against synthetic peptides derived from the IIIa sequence were used to localize these fragments. Rabbit anti-IIa63,5654 crossreacts with the same series of fragments (33-50 kD), separated under nonreducing conditions, and only the 50-kD fragment carried the amino-terminus of Ila, as evidenced by its reaction with rabbit anti-Illa1,-3. These results suggested that the autoantigenic epitope RA resides in the carboxy-terminal region ofthe 50-kD fragment. When this 50-kD fragment is affinity purified and reduced, it itselfgenerates fragments with apparent molecular masses of < 10, 33, 38, and 50 kD.
A logical explanation of these data is diagramed in Fig. 5 which depicts the probable relationship of the . 10, 33 and 50 kD fragments. Digestion ofthe cysteine-rich region ofIlIa must be limited to a handful of sites generating a limited number of fragments that are still held together by disulfide bonds. The largest fragment of 50 kD (under reduced conditions), which < 10 kDa [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Nfr. Although the amino acid sequence of II1a has been published, little information is available concerning the higher order structure of IIIa. It has been demonstrated that chymotryptic digestion of lIIa within the membrane of platelets produces a dipeptide consisting of a 20-kD amino-terminal fragment disulfide-bonded to a transmembrane 65-kD fragment that represents the carboxy-terminal half of the II1a molecule (33, 34) . The amino terminus ofthis 65-kD fragment is at residue 348 (33) . Our experimental conditions favor a more extensive proteolysis of MIIa thereby producing a truncated form of the above 65-kD fragment.
The hypothetical conformational features of the Ila sequence encompassing the 33-kD chymotryptic fragment (residues 420-654) can be analyzed using algorithms, based upon primary amino acid sequence, that predict secondary structure (35) , positions of beta turns (36) , chain flexibility (37), hydrophilicity (38) and the hydropathic index (39) . Using these analyses, the segment of II1a on or about the amino-terminus of the 33-kD fragment at arginine-479 can be described as: (a) a region that immediately follows a beta turn position at or about proline-464; (b) the region of greatest flexibility (B[norm] = 1.13); and (c) a point of high hydrophilicity (Ah = 1.88) and lowest hydropathy (h.i. = -25). Taken together, these results would predict that arginine-479 is located in an extended and exposed position within the 50-kD fragment, a finding that is consistent with its experimentally determined susceptibility to further cleavage by chymotrypsin.
The affinity-purified 50-kD fragment was used as solidphase antigen to detect other autoantibodies reactive with this fragment. By (13, 14) . In addition, two of eight patients with acute ITP had antibodies that bound to the 50-kD fragment. The finding of anti-lIb/Illa antibodies in acute ITP, albeit at lesser frequencies, is also consistent with a prior report (16 The identification of regions on I1bIlila that are autoimmunogenic in man provides opportunities to develop new diagnostic and therapeutic approaches to autoimmune thrombocytopenia. In this report, we have taken the first concrete steps toward identifying such autoantigenic regions. Further studies are being pursued to more precisely determine the number and kinds ofthese epitopes in the cysteine-rich 50-kD fragment derived from Ila.
